These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31815566)

  • 1. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 2. An updated patent review of BRD4 degraders.
    Ma Z; Zhang C; Bolinger AA; Zhou J
    Expert Opin Ther Pat; 2024 Oct; 34(10):929-951. PubMed ID: 39219068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
    Liang D; Yu Y; Ma Z
    Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Inhibitors as Anticancer Agents: A Patent Review.
    Ali I; Choi G; Lee K
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain-Containing Protein 4: A Druggable Target.
    Shi Y; Liu J; Zhao Y; Cao J; Li Y; Guo F
    Curr Drug Targets; 2019; 20(15):1517-1536. PubMed ID: 31215391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Privileged Scaffolds Targeting Bromodomain-containing Protein 4.
    Wang R; Wang YA; Xu YG; Shi L
    Curr Top Med Chem; 2022; 22(7):600-627. PubMed ID: 35139799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions.
    Jin W; Tan H; Wu J; He G; Liu B
    Drug Discov Today; 2022 Jan; 27(1):246-256. PubMed ID: 34438075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms.
    Tang J; Chen H; Fan H; Chen T; Pu C; Guo Y
    Bioorg Med Chem; 2024 Nov; 113():117929. PubMed ID: 39317007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
    Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
    Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.